All News

Radiation Shown to Improve Survival in Liver Cancer ‘For the First Time’
January 28, 2023

Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.

Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic Factors
January 28, 2023

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.

FDA Grants Approval to Elacestrant for ER+/HER2– Advanced Metastatic Breast Cancer
January 27, 2023

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer can now receive elacestrant as treatment following the FDA’s approval of the agent.

Expert Details 'Striking' Data When Using ctDNA to Predict Early Response in CRC
January 27, 2023

The use of circulating tumor DNA in patients with advanced colorectal cancer may provide early insight into who is and is not responding to treatment, according to an expert from Weill Cornell Medicine.

Survival of Patients With Inoperable Non–Small Cell Lung Cancer With Baseline Severe Pulmonary Dysfunction: Impacts of Thoracic Radiotherapy and Predictive Analysis for Acute Radiation Pneumonitis
January 27, 2023

Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.

Trastuzumab Deruxtecan Is Approved in EU for HER2-Low Metastatic Breast Cancer
January 27, 2023

The European Commission approval for trastuzumab deruxtecan in HER2-low metastatic breast cancer is based on data from the phase 3 DESTINY-Breast04 trial.

Adjuvant Chemo After Neoadjuvant Chemo/Surgery Linked With Survival in PDAC
January 27, 2023

Adjuvant chemotherapy following multiagent neoadjuvant chemotherapy and surgical resection produced better overall survival among patients with pancreatic ductal adenocarcinoma vs those who did not receive adjuvant treatment.

FDA OKs Adjuvant Pembrolizumab for Resected NSCLC
January 26, 2023

The FDA approved adjuvant pembrolizumab for the treatment of patients with resected non–small cell lung cancer, based on data from the phase 3 KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15-PEARLS trial.

FDA Gives Tamibarotene Fast Track Designation for High-Risk MDS
January 26, 2023

Tamibarotene is a first-in-class oral first-in-class selective retinoic acid receptor α agonist that is being evaluated in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome.